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Severe acute asthma (SAA) can lead to respiratory failure and can be fatal. For rational use of intravenous (IV) bronchodilators,
evidence regarding the pharmacokinetics and pharmacodynamics is lacking in children.(e use of a loading dose IV salbutamol is
not mentioned in any international guideline, and its use varies greatly between PICUs worldwide. We describe a 17-year-old
Caucasian female with SAA resulting in an out-of-hospital cardiac arrest. After basic life support and return of spontaneous
circulation, the ambulance administered oxygen, inhaled salbutamol, IV magnesium sulphate, and systemic corticosteroids.
Despite of this, she was still in severe respiratory distress.(erefore, a loading dose of IV salbutamol was administered, after which
an immediate improvement was observed. Having a loading dose of IV salbutamol available for emergency medical services use
for SAA in children with life-threatening SAA in the out-of-hospital setting is important to consider. Further study on the dose
and the eﬀect of a loading dose IV salbutamol in children with SAA is necessary.
1. Introduction
Severe acute asthma (SAA) is deﬁned as an acute asthma
exacerbation that does not respond to conventional
treatment with bronchodilators and systemic corticoste-
roids. SAA potentially progresses to respiratory failure and
can be fatal [1]. In the Netherlands, approximately 100
patients are admitted every year to a pediatric intensive
care unit (PICU) with an increasing incidence over the last
decade [2]. Inhaled beta-agonists combined with steroid
treatment are the mainstay of SAA treatment. If the patient
does not respond to initial inhaled therapy there are
several therapeutic options which are not standardized
over PICUs worldwide. Intravenous (IV) salbutamol in
children is an optional treatment with a lack of evidence
regarding the pharmacokinetics (PK) and pharmacody-
namics (PD) [3].
2. Case
A 17-year-old Caucasian female presented with a known
history of severe asthma with multiple hospital admissions
due to asthma in the past (not requiring admission to the
PICU). She had a history of allergies for pets, tree pollen,
grass, and house dust mite for which she used an oral an-
tihistamine (desloratadine). (ere were no pets at home and
no carpets. Recently, she started smoking again. Mainte-
nance treatment consisted of a combination of inhaled
corticosteroids with a long-acting beta2-agonist (beclome-
thasone/formoterol, 200/12mcg twice daily) and a short-
acting beta2-agonist as needed (400mcg of salbutamol).
(ere was a lack of medication adherence, as reported by
herself and her parents. Pulmonary function testing two
weeks prior to her cardiac arrest demonstrated severe ob-
struction (Figure 1).
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In the weeks prior to the event, she complained of in-
creasing shortness of breath and used salbutamol more
frequently. At a scheduled visit to the pediatric pulmonol-
ogist, three weeks before the event, antibiotics and an oral
course of prednisone for two weeks were prescribed for an
asthma exacerbation. (e symptoms did not fully disappear.
A week after she ﬁnished the prednisone course, she woke up
in the middle of the night because of respiratory distress and
started with nebulization with salbutamol every 3 hours after
her parents had consulted the emergency department (ED)
by phone. In the daytime she was feeling better. (e fol-
lowing night, again, she was in severe respiratory distress.
She subsequently collapsed in front of her parents. Her
parents noticed that her skin and lips turned blue, she
stopped breathing, and there were no signs of life. Basic life
support (BLS) was started by her father, for approximately
6minutes.
On arrival of the ambulance there was return of spon-
taneous circulation (ROSC). Her oxygen saturation level was
74% in room air, with a heart rate of 180 beats per minute
(bpm). She looked grey and was unresponsive. Treatment
consisted of oxygen (with a nonrebreather mask (NRM)),
continuous inhalation with salbutamol (15mg/hr) and an-
ticholinergics (ipratropium bromide, 4 consecutive doses of
0.5mg), and IV hydrocortisone (200mg). At the time of
mobile medical team (MMT) arrival (T10minutes), she had
a persistently increased work of breathing with oxygen
saturation levels of 90% with a NRM with a ﬂow of 6 L/min.
(ere was sinus tachycardia, with a heart rate of 150 bpm
and a blood pressure of 160/100mmHg. She was very agi-
tated, unable to speak more than 1-2 words, and had a
reduced level of consciousness. On auscultation, there were
diminished breath sounds with wheezing during a pro-
longed expiratory phase. IV magnesium sulphate (MgSO4)
(2 grams) was administered (based on an estimated body
weight of 60 kg), and continuous nebulization with salbu-
tamol and ipratropium bromide was continued. Because
severe respiratory distress persisted, a loading dose of IV
salbutamol (5mcg/kg, 300mcg) was given over approxi-
mately 10minutes. After this loading dose of IV salbutamol
an immediate improvement was seen by the MMT. Her
oxygen saturation level increased from 90% to 95%, and the
heart rate decreased from 150 bpm to 110 bpm with a blood
pressure of 140/90mmHg. She was able to speak full sen-
tences and had a normal level of consciousness. She was
transferred to the hospital with oxygen supply (NRM) and
continuous nebulization with salbutamol and ipratropium
bromide.
At the time of arrival in the ED (T60minutes) her vital
parameters were normal (Table 1). She was able to speak full
sentences. On auscultation, there were mild diminished
breath sounds with wheezing end-expiratory. A capillary
blood gas showed a pH 7.29, PCO2 5.7 kPa (42.8mmHg),
PO2 5.6 kPa (42mmHg), bicarbonate 20.7mmol/L, base
excess –6, lactate 3.6mmol/L, and a glucose level of
13.1mmol/L (236mg/dL). (e X-ray showed hyperinﬂation
and prominence of the hilar vasculature with a focal atel-
ectasis in the middle lobe (Figure 2). Treatment at the ED
consisted of oxygen supply, continuous salbutamol nebu-
lization, and prednisone. Because there were no signs of
respiratory distress anymore, no continuous infusion with
salbutamol was started. Due to the severity of the SAA with
the need for cardiopulmonary resuscitation, she was ad-
mitted to the PICU with continuation of the same treatment
(oxygen, nebulization with salbutamol, and systemic corti-
costeroids). With 2 L/min of low-ﬂow oxygen via a nasal
cannula her oxygen saturations remained >95%.
Five hours after PICU admission, she was switched to
hourly nebulization. (e following day, she was transferred
to the general pediatric ward with nebulization every two
hours. Oxygen supply was discontinued after 48 hours. After
5 days, she was discharged home with a course of oral
prednisone (15 days in total), 3 inhalations of beclometha-
sone/formoterol twice daily, and 4 inhalations of salbutamol
four times daily.
One week after hospital discharge, she was able to
perform all normal daily activities.
3. Discussion
(is case report is illustrative for the potential beneﬁt of a
loading dose of IV salbutamol in children with life-threat-
ening SAA in the out-of-hospital setting. (is patient de-
veloped a SAA with respiratory failure most likely based on
medication nonadherence combined with smoking. Within
minutes, there was a witnessed cardiac arrest probably due to
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Figure 1: Lung function two weeks prior to the event.
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Table 1: Vital parameters.
Arrival ambulance (T0) Arrival MMT (T10minutes) Departure MMT(T40minutes)
Arrival ED
(T60minutes)
Work of breathing Increased work ofbreathing Increased work of breathing — Normal
Oxygen saturation (%) 74 90 95 99
Oxygen supply — 6 L/min 100% 6 L/min 100% 6 L/min 100%
HF (min) 180 150 110 100
Blood pressure
(mmHg) — 160/100 140/90 130/80
Level of consciousness
Agitated
Not able to speak more than 1-2
words
Normal
Able to speak full
sentences
Figure 2: X-ray PICU admission.
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hypoxemia. Bystander BLS led to ROSC. (ere was a lack of
response to conventional treatment, but an immediate and
sustained response of her vital parameters and overall
clinical picture to a loading dose of IV salbutamol.
Severe bronchial constriction may decrease the delivery
of inhaled beta-agonists to the distal airways in children with
SAA. (erefore, it is likely that a loading dose of IV sal-
butamol can lead to therapeutic concentration of salbutamol
in blood immediately after infusion and thus, a more ef-
fective bronchodilation eﬀect. (e optimal dosage of a
loading dose of IV salbutamol is yet to be discovered.
Following 2 current national guidelines [4, 5], children
receive a 10–15mcg/kg loading dose over 5–10min, with a
maximum of 250mcg. (e loading dose advice is based on a
few studies looking at the eﬀect of a bolus of IV salbutamol
[6, 7] or terbutaline [8] of 10–15mcg/kg on asthma scores
and hospital admission, showing a small eﬀect on time to
discharge from hospital or PICU, duration of nebulization of
salbutamol, and clinical asthma scores. Furthermore, there
were no statistical diﬀerences in side eﬀects. Our patient
received a loading dose of IV salbutamol of 5mcg/kg
(300mcg). Although this is not high on a per kg basis, it is
above the recommended maximum dose. In our patient, this
lower dose led to a signiﬁcant eﬀect. Salbutamol exists as a
pair of enantiomers, (R)- and (S)-enantiomer. (e (R)-en-
antiomer is a potent B2-adrenoceptor stimulant, with little or
no activity from the (S)-enantiomer. R-salbutamol is me-
tabolized up to 12 times faster than S-salbutamol, which
leads to relatively higher plasma concentrations of S-sal-
butamol [9].
Interestingly, the patient’s heart rate decreased after
continuous inhalation with salbutamol and even further,
after a loading dose of IV salbutamol (from 180 bpm to
100 bpm), the opposite eﬀect to what one would expect with
the use of salbutamol. (is could be mainly explained by the
dramatic improvement of respiratory distress, as often seen
in our clinical practice. Although our patient did not receive
continuous infusion of salbutamol, a continuous IV infusion
of salbutamol after the loading dose is recommended. Al-
though not studied in the literature to date, it is likely to
maintain therapeutic concentrations of the drug in blood at
least during the transportation to the PICU. (e use of
adjunct therapies in the treatment of children with SAA is
not standardized and varies greatly worldwide [10, 11].
Adjunct therapies which are often used are MgSO4, meth-
ylxanthines (e.g., theophylline), and a loading dose of IV
salbutamol, even though these therapies show inconclusive
results [3, 12]. In a recent survey, IV salbutamol loading dose
was used by 18% of respondents from European PICUs, so it
is not standard of care (under revision). Although there are
many ways to treat a child with SAA, we showed that in an
out-of-hospital setting a loading dose of IV salbutamol can
be beneﬁcial. Having salbutamol available for emergency
medical services (EMS) use for SAA may be important to
consider. Salbutamol is easy to administer in the out-of-
hospital setting with very few serious side eﬀects. Common
adverse reactions associated with salbutamol therapy include
tremor, hypokalaemia, increased lactate level, hyper-
glycaemia, and sinus tachycardia [3]. In adults, salbutamol
toxicity is associated with blood concentrations >30 ng/mL
with a putative lethal level of >160 ng/ml. However, in
children very high blood salbutamol concentrations (196–
586 ng/mL) have been recorded without serious side eﬀects
[3]. Further research is needed to evaluate the eﬀect and the
dosage of a loading dose of IV salbutamol in children.
4. Conclusion
In children with life-threatening SAA in the out-of-hospital
setting a loading dose of IV salbutamol should be consid-
ered. Further study on the dose and the eﬀect of a loading
dose IV salbutamol in children with SAA is necessary.
Consent
(e patient and both of her parents gave written informed
consent for publication.
Conflicts of Interest
(e authors declare that they have no conﬂicts of interest.
References
[1] V. Kaza, V. Bandi, and K. K. Guntupalli, “Acute severe
asthma: recent advances,” Current Opinion in Internal
Medicine, vol. 6, no. 2, pp. 189–195, 2007.
[2] S. A. Boeschoten, C. M. P. Buysse, P. J. F. M. Merkus et al.,
“Children with severe acute asthma admitted to Dutch PICUs:
a changing landscape,” Pediatric Pulmonology, vol. 53, no. 7,
pp. 857–865, 2018.
[3] E. S. Starkey, H. Mulla, H. M. Sammons, and H. C. Pandya,
“Intravenous salbutamol for childhood asthma: evidence-
based medicine?,” Archives of Disease in Childhood, vol. 99,
no. 9, pp. 873–877, 2014.
[4] BTS/SIGN, British Guideline on the Management of Asthma,
British (oracic Society, London, UK, 2018.
[5] National Asthma Council Australia, Australian Asthma
Handbook, National Asthma Council Australia, Mel-
bourne, Australia, 2019, https://www.asthmahandbook.
org.au/acute-asthma/clinical/add-on-treatment.
[6] G. J. Browne, A. S. Penna, X. Phung, and M. Soo, “Rando-
mised trial of intravenous salbutamol in early management of
acute severe asthma in children,” +e Lancet, vol. 349,
no. 9048, pp. 301–305, 1997.
[7] G. J. Browne, L. Trieu, and P. Van Asperen, “Randomized,
double-blind, placebo-controlled trial of intravenous salbu-
tamol and nebulized ipratropium bromide in early manage-
ment of severe acute asthma in children presenting to an
emergency department,” Critical Care Medicine, vol. 30, no. 2,
pp. 448–453, 2002.
[8] A. L. Bogie, D. Towne, P. M. Luckett, T. J. Abramo, and
R. A. Wiebe, “Comparison of intravenous terbutaline versus
normal saline in pediatric patients on continuous high-dose
nebulized albuterol for status asthmaticus,” Pediatric Emer-
gency Care, vol. 23, no. 6, pp. 355–361, 2007.
[9] D. W. Boulton and J. P. Fawcett, “(e pharmacokinetics of
levosalbutamol: what are the clinical implications?,” Clinical
Pharmacokinetics, vol. 40, no. 1, pp. 23–40, 2001.
[10] F. E. Babl, N. Sheriﬀ, M Borland et al., “Paediatric acute
asthma management in Australia and New Zealand: practice
patterns in the context of clinical practice guidelines,”
4 Case Reports in Pediatrics
Archives of Disease in Childhood, vol. 93, no. 4, pp. 307–312,
2008.
[11] K. J. Rehder, “Adjunct therapies for refractory status asth-
maticus in children,” Respiratory Care, vol. 62, no. 6,
pp. 849–865, 2017.
[12] D. K. L. Cheuk, T. C. H. Chau, and S. L. Lee, “A meta-analysis
on intravenous magnesium sulphate for treating acute
asthma,” Archives of Disease in Childhood, vol. 90, no. 1,
pp. 74–77, 2005.
Case Reports in Pediatrics 5
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
